12.50USD-0.79%Mkt Cap: 1.77B USDP/E: —Last update: 2026-05-26
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly inters…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap1.77B USD
Enterprise Value1.43B USD
Revenue (TTM)66.09M USD
Gross Profit-230.67M USD
Net Income (TTM)-412.69M USD
Revenue/Share0.5890 USD
Last Price12.50 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees377
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS45826J1051
Valuation
P/E (Trailing)—
P/E (Forward)-6.47
PEG—
EV/EBITDA-3.48
EV/Revenue21.68
P/S26.15
P/B2.40
EPS (TTM)-3.52
EPS (Forward)-1.91
52W Range
6.83026% of range28.25
52W High28.25 USD
52W Low6.830 USD
Profitability
Gross Margin0.00%
Oper. Margin-668.07%
EBITDA Margin0.00%
Profit Margin-609.85%
ROE-61.47%
ROA-49.01%
Growth
Revenue Growth-9.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-394.74M USD
CapEx (TTM)1.13M USD
FCF Margin-355.92%
FCF Yield-13.31%
Net Debt-295.50M USD
Net Debt/EBITDA0.72
Balance Sheet
Debt/Equity0.14
Current Ratio6.10
Quick Ratio5.04
Book Value/Sh5.155 USD
Cash/Share2.691 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.1 (Buy)
Target (Mean)26.65 USD
Target Range8.000 USD – 95.00 USD
# Analysts20
Ownership
Shares Out.139.72M
Float134.16M
Insiders3.83%
Institutions76.70%
Short Interest
Short Ratio6.8d
Short % Float39.28%
Short % Out.31.16%
Shares Short43.53M
Short (prev mo.)38.95M
Technical
SMA 5013.56 (-7.8%)
SMA 20013.22 (-5.4%)
Beta1.93
S&P 52W Chg28.31%
Avg Vol (30d)7.53M
Avg Vol (10d)7.50M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—